On this episode of Why It Matters, we discuss how aging populations across the globe are driving public and private investment into longevity research and biotechnology innovation.
Host:
Gabrielle Sierra, director of podcasting, Council on Foreign Relations (CFR)
Guest:
Lakshmy Ramakrishnan, associate fellow, Observer Research Foundation
Body: Among wealthy nations worldwide, populations are aging and the race to extend the duration of a healthy life has become a matter of national strategy, not just personal wellness. From Russia’s planned “anti-aging vaccine” to China’s state-led longevity initiative and a U.S. biotech industry driven largely by private billionaires, many countries are betting that biotech innovations will lead to major breakthroughs. But is the effort based in real science, or simply science fiction?
Read More:
“Charting the Future of American Biotechnology,” National Security Commission on Emerging Biotechnology
Jack Burnam, Johanna Yang, “U.S. at Risk of Falling Behind China in Biotechnology,” Foundation for the Defense of Democracies
Bojan Pancevski, “Inside Putin's $26 Billion Quest for Longevity,” Wall Street Journal
Borje Ljunggren, “A Rapidly Aging World – and the Awaiting Demographic Implosion,” Harvard Kennedy School
Want to keep up with Why It Matters? Sign up to receive an email alert when new episodes drop.
Why It Matters is a production of the Council on Foreign Relations. The opinions expressed on the show are solely those of the host and guests, not of the Council, which takes no institutional positions on matters of policy.